Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 4,807 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)

NCT02124759
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Sevelamer, Synbiotic, Maltodextrin, High Fat diet, Low Fat diet
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 28, 2026, 5:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Registry for Asthma Characterization and Recruitment 2

NCT02513264
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
1,384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

NCT05018806
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Rilzabrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Northridge, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 28, 2026, 5:21 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

NCT07024784
View directory record Official record
Conditions
Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
Interventions
IMGN151, Carboplatin, Bevacizumab, Olaparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Minneapolis, Minnesota + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 4 Interventional

GSK BHR Study (Sont - Second Study)

NCT01324362
View directory record Official record
Conditions
Asthma
Interventions
Placebo, FP 100mcg, FP 250mcg, FP 500mcg, FSC 100/50mcg, FSC 250/50mcg, FSC500/50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

Borage and Echium Seed Oils for Asthma

NCT01560988
View directory record Official record
Conditions
Asthma
Interventions
Borage and Echium Seed Oils, Corn oil pills
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 28, 2026, 5:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ozone and Rhinovirus-Induced Disease in Asthmatics

NCT00013715
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2003
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2008 · Synced Oct 28, 2026, 5:21 AM EDT
Not listed Phase 4 Interventional

The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils

NCT00673218
View directory record Official record
Conditions
Allergy
Interventions
Placebo, Xolair
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 6, 2012 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Results available

To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.

NCT04848662
View directory record Official record
Conditions
Asthma
Interventions
BDA MDI (PT027) 160/180 μg, Pulmicort Respules 0.5 MG/ML Inhalation Suspension
Drug
Lead sponsor
Bond Avillion 2 Development LP
Industry
Eligibility
4 Years to 8 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Boerne, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 28, 2026, 5:21 AM EDT
Active, not recruiting Phase 4 Interventional

Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia

NCT06986603
View directory record Official record
Conditions
Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery
Interventions
Glucagon for Injection (Fresenius Kabi USA)
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 28, 2026, 5:21 AM EDT
Completed No phase listed Observational

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

NCT00186940
View directory record Official record
Conditions
Leukemia, Lymphoma, Tumor Lysis Syndrome, Hyperuricemia
Interventions
Rasburicase
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Palo Alto, California • San Diego, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Progressive Metabolic Adaptations to Low Intensity Exercise Training and Weight Loss

NCT01452074
View directory record Official record
Conditions
Obesity
Interventions
Exercise Training, Weight Loss with continued Exercise Training
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 28, 2026, 5:21 AM EDT
Not listed Not applicable Interventional

Acceptability/Feasibility Testing of SCAR

NCT04859790
View directory record Official record
Conditions
Social Anxiety
Interventions
Social Concerns Appraisal Retraining
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Not applicable Interventional Results available

The Study is Enrolling Kids From 8 to 17 Years Old. The BreathSmart Device Attaches to the Inhaler to Measure Adherence.

NCT03734861
View directory record Official record
Conditions
Asthma
Interventions
BreatheSmart System, Standard of Care
Device · Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control

NCT04529473
View directory record Official record
Conditions
Pre Diabetes, Impaired Glucose Tolerance, Insulin Sensitivity, Insulin Resistance, Glucose Metabolism Disorders, Metabolic Syndrome
Interventions
Eubacterium hallii, Placebo
Dietary Supplement · Other
Lead sponsor
Atlantia Food Clinical Trials
Industry
Eligibility
21 Years to 69 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

NCT03028350
View directory record Official record
Conditions
Asthma, Aspirin-Induced
Interventions
Ifetroban Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
16
States / cities
Tucson, Arizona • Lancaster, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 28, 2026, 5:21 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effect of Blueberries on Enhancing Insulin Sensitivity in Humans: A Pilot Study

NCT01005420
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Blueberry Powder, Placebo
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 28, 2026, 5:21 AM EDT
Terminated Phase 4 Interventional Results available

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

NCT05200403
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2%, Vehicle treatment, Accelerometry device for children, Accelerometry device for adult caregivers
Drug · Device
Lead sponsor
Boston University
Other
Eligibility
3 Months to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of a Probiotic Supplement to Prevent Asthma in Infants

NCT00113659
View directory record Official record
Conditions
Asthma
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
Montefiore Medical Center
Other
Eligibility
1 Day to 4 Days
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 3 Interventional

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

NCT00393991
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10, Placebo
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Pell City, Alabama • Scottsdale, Arizona • Cypress, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

NCT01573624
View directory record Official record
Conditions
Asthma
Interventions
FF/GSK573719, FF, FF/VI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
St Louis, Missouri • Medford, Oregon • Orangeburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Inhaler Trainer Efficacy Study

NCT06461403
View directory record Official record
Conditions
Asthma, Copd, Acute Exacerbation of COPD
Interventions
Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction
Device · Other
Lead sponsor
Koronis Biomedical Technologies
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

NCT00420342
View directory record Official record
Conditions
Postmenopause, Hypertension, Pre-Hypertension
Interventions
Drospirenone/17ß-estradiol (Angeliq, BAY86-4891), SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Greenbrae, California • San Diego, California • Daytona Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes

NCT02023918
View directory record Official record
Conditions
Diabetes, Metabolic Syndrome, Insulin Resistance
Interventions
pegvisomant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 28, 2026, 5:21 AM EDT